[Role of chemotherapy in the treatment of gastric adenocarcinoma].
In spite of the progress achieved in endoscopic detection and surgical techniques, the prognosis of gastric adenocarcinomas remains poor. To improve the results obtained, one of the most important lines of research is chemotherapy, but its place in the management of these tumours is still controverted. Apart from 5-fluorouracil, other active drugs recently developed (e.g. adriamycin, mitomycin, nitroso-ureas and cis-platinum) have been entered into new protocols and tested. The results at present available in patients with metastases are 40 to 50% complete or partial objective responses lasting for 4 to 16 months. They justify the use of these drugs, provided the patients' comfort is improved after the first two cycles. The place of adjuvant chemotherapy after complete surgical resection of gastric adenocarcinomas is still debated. Only 3 out of 13 randomized trials have demonstrated a longer survival in the treated group. Further controlled trials are required, using the most effective protocols, to determine their advantages and to find out which subgroups of patients are likely to benefit from chemotherapy.
Rougier
P
P
Gisselbrecht
C
C
Zeitoun
P
P
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000628:therapy; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D006801:Humans; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000628:therapy; D013997:Time Factors
D000970:Antineoplastic Agents
Place de la chimiothérapie dans le traitement des adénocarcinomes gastriques.